Hepatitis C virus treatment and injection drug users: It is time to separate fact from fiction

Annals of Internal Medicine

Volumn 163, Issue 3, 2015, Pages 224-225

  McCance Katz, Elinore F ^a   Valdiserri, Ronald O ^b  

^a SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; OPIATE;

ANTIVIRAL THERAPY; DRUG ABUSE; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; INJECTION DRUG USER; MEDICAL HISTORY; NOTE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; REINFECTION; RELAPSE; SUBSTANCE ABUSE; TREATMENT OUTCOME; COMPLICATION; DRUG COST; DRUG USE; ECONOMICS; HEPATITIS C, CHRONIC; OPIATE ADDICTION;

ANTIVIRAL AGENTS; DRUG COSTS; DRUG USERS; HEPATITIS C, CHRONIC; HUMANS; OPIOID-RELATED DISORDERS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84938773146     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0007     Document Type: Note

References (9)

1. American Association for the Study of Liver Diseases. Recommendations for Testing, Managing, and Treating Hepatitis C. 2014. Accessed at www.hcvguidelines.org on 21 November 2014.
2. Venteicher W. Most Illinois Medicaid patients denied new hepatitis C drugs. Chicago Tribune. 19 November 2014. Accessed at http://kaiserhealthnews.org/news/most-illinois-medicaid-patients-denied-new-hepatitis-c-drugs on 21 November 2014.
3. Malta M, Magnanini MM, Strathdee SA, Bastos FI. Adherence to antiretroviral therapy among HIV-infected drug users: a metaanalysis. AIDS Behav. 2010;14:731-47. [PMID: 19020970] doi:10.1007/s10461-008-9489-7
4. Ellwood M. Restrictions to HCV Treatment in State Medicaid Programs. Cambridge, MA: Center for Health Law and Policy Innovation, Harvard Law School; 2014. Accessed at www.chlpi.org/ wp-content/uploads/2014/01/Malinda-Ellwood-Restrictions-to-HCVTreatment-in-State-Medicaid-Programs-11.15.14.pdf on 21 November 2014.
5. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis. 2013;56:806-16. [PMID: 23223596] doi:10.1093/cid/cis1007
6. Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37:32-40. [PMID: 19038524] doi:10.1016/j.jsat.2008.09.009
7. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57 Suppl 2:S80-9. [PMID: 23884071] doi:10.1093/cid/cit306
8. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol. 2010;25: 1281-4. [PMID: 20594256] doi:10.1111/j.1440-1746.2010.06238.x
9. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207-25. [PMID: 22873183] doi:10.1080/10550887.2012.694598